ProCE Banner Activity


We’ve Got Your Back: Optimizing the Management of Axial Spondyloarthritis

PCE On Demand Live Presentation

Axial spondyloarthritis (axSpA) is a chronic inflammatory arthritis characterized by back pain, sacroiliitis, excessive spinal bone formation, and joint damage. Despite its prevalence, with an estimated 1.7-2.7 million people in the United Stated impacted alone, many experience significant diagnostic and treatment delays. In recent years, many novel therapies for axSpA have been approved by the FDA which are proven to improve symptoms, decrease disease activity, and potentially delay disease progression. Tune in to this on-demand webcast to hear our interdisciplinary expert panel review the latest literature and guideline recommendations for detecting, diagnosing, and treating axSpA early for improved patient and disease outcomes.

In collaboration with the Society of Physician Assistants in Rheumatology

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: October 19, 2022

Expiration: October 18, 2023

No longer available for credit.



Ethan Craig

Ethan Craig, MD, MHS

Assistant Professor of Clinical Medicine
Division of Rheumatology
University of Pennsylvania
Vice Chief for Clinical Affairs (Rheumatology)
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Shannon Ghizzoni

Shannon Ghizzoni, PA-C

Physician Assistant
Columbus Arthritis Center
Columbus, Ohio

Jennifer Simpson

Jennifer Simpson, DNP

Nurse Practitioner
Arizona Arthritis & Rheumatology Associates
Phoenix, Arizona


This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Provided by

ProCE Banner


Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

NPs and PAs specializing in rheumatology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the clinical signs, symptoms, risk factors, and imaging characteristics of axSpA to facilitate early diagnosis and treatment initiation

  • Evaluate patients with chronic back pain for axSpA using the latest guideline recommendations for the diagnosis of axSpA

  • Evaluate patients for the appropriate use of new and emerging treatment options and appropriately monitor for adverse events


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Ethan Craig, MD, MHS: consultant/advisor/speaker: Amgen, Calico Labs, Janssen, Novartis.

Shannon Ghizzoni, PA-C: consultant/advisor/speaker: AbbVie, Amgen, Novartis.

Jennifer Simpson, DNP: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Horizon, Janssen.

None of the members of the PACE or PCE staff have any relevant financial relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: October 19, 2022
Expiration date: October 18, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange, Partners for Advancing Clinical Education, or any educational supporter.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 18, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.